Home Cart 0 Sign in  

[ CAS No. 1393477-72-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 1393477-72-9
Chemical Structure| 1393477-72-9
Structure of 1393477-72-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1393477-72-9 ]

Related Doc. of [ 1393477-72-9 ]

Alternatived Products of [ 1393477-72-9 ]

Product Details of [ 1393477-72-9 ]

CAS No. :1393477-72-9 MDL No. :MFCD27987944
Formula : C17H11F6N7O Boiling Point : -
Linear Structure Formula :- InChI Key :DEVSOMFAQLZNKR-RJRFIUFISA-N
M.W : 443.31 Pubchem ID :71481097
Synonyms :
KPT-330;ATG-010

Calculated chemistry of [ 1393477-72-9 ]

Physicochemical Properties

Num. heavy atoms : 31
Num. arom. heavy atoms : 17
Fraction Csp3 : 0.12
Num. rotatable bonds : 8
Num. H-bond acceptors : 11.0
Num. H-bond donors : 2.0
Molar Refractivity : 94.07
TPSA : 97.62 Ų

Pharmacokinetics

GI absorption : None
BBB permeant : None
P-gp substrate : None
CYP1A2 inhibitor : None
CYP2C19 inhibitor : None
CYP2C9 inhibitor : None
CYP2D6 inhibitor : None
CYP3A4 inhibitor : None
Log Kp (skin permeation) : None cm/s

Lipophilicity

Log Po/w (iLOGP) : None
Log Po/w (XLOGP3) : None
Log Po/w (WLOGP) : 5.39
Log Po/w (MLOGP) : None
Log Po/w (SILICOS-IT) : None
Consensus Log Po/w : None

Druglikeness

Lipinski : None
Ghose : None
Veber : None
Egan : None
Muegge : None
Bioavailability Score : None

Water Solubility

Log S (ESOL) : None
Solubility : None mg/ml ; None mol/l
Class : None
Log S (Ali) : None
Solubility : None mg/ml ; None mol/l
Class : None
Log S (SILICOS-IT) : None
Solubility : None mg/ml ; None mol/l
Class : None

Medicinal Chemistry

PAINS : None alert
Brenk : None alert
Leadlikeness : None
Synthetic accessibility : None

Safety of [ 1393477-72-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1393477-72-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1393477-72-9 ]
  • Downstream synthetic route of [ 1393477-72-9 ]

[ 1393477-72-9 ] Synthesis Path-Upstream   1~9

  • 1
  • [ 1388842-44-1 ]
  • [ 54608-52-5 ]
  • [ 1393477-72-9 ]
YieldReaction ConditionsOperation in experiment
83% With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In ethyl acetate; acetonitrile at 0 - 25℃; for 3 h; In a 3-L, 3-necked, round-bottomed flask were charged 60.0 gr (Z)-3-(3-(3,5- bis(trifluoromethyl)phenyl)- 1 H- 1,2, 4-triazol- 1 -yl)acrylic acid (SLN- 105, prepared according to examples 27), Ethyl acetate (0.42 lit, 7V) and Acetonitrile (0.3 lit,5V) at 20-25°C. Charged 2-hydrazino pyrazine (19.8 gr, 1.05 eq) then cooled to 0 to 5°C. Charged EDC .HC1 (1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride) (49. lgr 1 .Seq) at 0 to 5°C. The reaction mass was stirred for 3hrs and monitored by HPLC (till SLN-105 NMT 1.0percent). Once the reaction completes, charge water (0.2lit, 2V) and stirred for 15-30 mm at 15-20°C, settled and separated the organic layer. Collected the organic layer and washed with sodium bicarbonate solution (0.Slit, SV). Finally washed the organic layer with water (0.2lit, 2 V) and combined the collected organic layer containing the product. The solvent is distilled off under vacuum at 50 to 60°C for 30 mm. To the obtained solid, added absolute Ethanol (0.6lit, 1OV) and stirred for 30mm at 20-25°C then cooled to 0-5°C and stirred for 1 hr at 0-5°C. Filtered the compound under vacuum at 20-25°C and washed with Ethanol (0.2lit, 2V). The wet cake was dried at 55-60°C under vacuum (600 to 700 mm Hg) for 4 hrs. (Yield 83percent).
16% With 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide; N-ethyl-N,N-diisopropylamine In dichloromethane; ethyl acetate at -40℃; for 0.5 h; Example 2: Synthesis of (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-lH-l,2,4-triazol- 1 -yl)-N'-(pyrazin-2-yl)acr lohydrazide (1-3 .A 50-mL, 3-necked, round-bottomed flask was charged with a suspension of (Z)-3-(3- (3,5-bis(trifluoromethyl)phenyl)-lH-l,2,4-triazol-l-yl)acrylic acid (0.200 g) in 1 :1 CH2C12: AcOEt (25 mL). 2-Hydrazinopyrazine (0.062 g) was added at -40 °C followed by T3P (50percent) (0.432g) and DIPEA (0.147 g). The reaction mixture was stirred for 30 min at -40 °C before being concentrated under reduced pressure (35 °C, 20 mmHg). The crude oil was purified by preparative TLC using 5percent MeOH in CH2C12 as mobile phase (under ammonia atmosphere) to afford 40 mg (yield: 16percent) of (Z)-3-(3-(355-bis(trifluoromethyl)phenyl)-lH-l,2,4-triazol-l- yl)-N'-(pyrazin-2-yl)acrylohydrazide. 1H NMR (400 MHz, DMSO-d6) δ ,10.53 (s, 1H), 9.59 (s, 1H), 9.14 (s, 1H), 8.53 (s, 2H), 8.29 (s, 1H), 8.13 (s, 1H), 8.06-8.07 (m, 1H), 7.92-7.93 (d, J=2.8 Hz, 1H), 7.51-7.53 (d, J=10.4 Hz, 1H), 6.07-6.10 (d, J=10.4 Ηζ,ΙΗ); LCMS for CnHi2F6N70 [M+H]+ predicted: 444.31, found: 444.49 (RT 2.70 min, purity: 95.78percent).
7 g With 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide; N-ethyl-N,N-diisopropylamine In ethyl acetate; acetonitrile at 0℃; for 2.5 h; Example-4: Preparation of Selinexor (0507) (0508) (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1 H-1 ,2,4-triazol-1 -yl)acrylic acid (10 g) was combined with a mixture of acetonitrile (1 00 mL) and ethyl acetate (50 mL) then added the 2-hydrazinylpyrazine (3.76 g) and stirred for 5 min. Reaction mixture was cooled to 0°C and diisopropyl ethyl amine (16.63 ml) and then Propylphosphonic anhydride (T3P, 33.31 mL) was added at 0°C and stirred the reaction mixture for 2.5 hours at the same temperature. After completion of the reaction, the reaction mixture was quenched with cold water (100 mL) and extracted the product with ethyl acetate (2 x 150 mL). The combined organic layer was dried over sodium sulphate and evaporated the solvent under vacuum at 40°C to obtain the crude product as yellow syrup. The obtained crude product was combined with dichloromethane (1 00 mL) and filtered the solid and washed with dichloromethane (2 x 50 mL). The solid was dried under vacuum at 40°C to obtain the title compound with purity by HPLC of 99.86percent. Yield : 7 g
Reference: [1] Patent: WO2018/129227, 2018, A1, . Location in patent: Paragraph 00196; 00197; 00215; 00216; 00218
[2] Patent: WO2013/19548, 2013, A1, . Location in patent: Page/Page column 56-57
[3] Drugs of the Future, 2014, vol. 39, # 10, p. 685 - 692
[4] Patent: WO2017/118940, 2017, A1, . Location in patent: Page/Page column 61
  • 2
  • [ 1333154-10-1 ]
  • [ 1393477-72-9 ]
YieldReaction ConditionsOperation in experiment
0.158 g With 1,4-diaza-bicyclo[2.2.2]octane In N,N-dimethyl-formamide for 3.5 h; 50ml three-necked flask was added 0.2g compound 1, 0.24gDBACO, 20mlDMF, stirred to dissolve, to the reaction systemDropping the compound obtained in Step 8, a DMF solution, after the addition was completed, stirring was continued for 3.5 hours; After the reaction, to the system plus20ml of water and 50ml of ethyl acetate, the organic phase is evaporated to dryness, and then ethyl acetate and petroleum ether are recrystallized to obtain 0.158g of compound 5Rate of 50.9percent.
Reference: [1] Patent: CN106831731, 2017, A, . Location in patent: Paragraph 0018; 0019; 0029; 0030; 0037; 0038; 0045; 0046
  • 3
  • [ 1333154-10-1 ]
  • [ 1393477-72-9 ]
Reference: [1] Patent: WO2013/19548, 2013, A1,
[2] Patent: WO2013/19548, 2013, A1,
[3] Drugs of the Future, 2014, vol. 39, # 10, p. 685 - 692
[4] Patent: WO2017/118940, 2017, A1,
[5] Patent: WO2018/129227, 2018, A1,
  • 4
  • [ 54608-52-5 ]
  • [ 1393477-72-9 ]
Reference: [1] Patent: WO2016/25904, 2016, A1, . Location in patent: Paragraph 00326
  • 5
  • [ 27126-93-8 ]
  • [ 1393477-72-9 ]
Reference: [1] Patent: WO2013/19548, 2013, A1,
[2] Patent: WO2013/19548, 2013, A1,
[3] Drugs of the Future, 2014, vol. 39, # 10, p. 685 - 692
  • 6
  • [ 317319-15-6 ]
  • [ 1393477-72-9 ]
Reference: [1] Patent: WO2013/19548, 2013, A1,
[2] Patent: WO2013/19548, 2013, A1,
[3] Drugs of the Future, 2014, vol. 39, # 10, p. 685 - 692
  • 7
  • [ 54608-52-5 ]
  • [ 1333154-10-1 ]
  • [ 1393477-72-9 ]
Reference: [1] Patent: WO2016/25904, 2016, A1, . Location in patent: Paragraph 00326
  • 8
  • [ 1333152-22-9 ]
  • [ 1393477-72-9 ]
Reference: [1] Patent: WO2013/19548, 2013, A1,
  • 9
  • [ 22227-26-5 ]
  • [ 1393477-72-9 ]
Reference: [1] Patent: WO2018/129227, 2018, A1,
Same Skeleton Products
Historical Records